SW
TGTX icon

SlateStone Wealth’s TG Therapeutics TGTX Stock Holding History

SlateStone Wealth’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,447
Closed -$274K – 196
2021
Q4 		$274K Sell
14,447
-5,100
-26% -$132K 0.06% 154
2021
Q3 		$651K Buy
19,547
+100
+0.5% +$3.09K 0.15% 104
2021
Q2 		$754K Sell
19,447
-800
-4% -$31.4K 0.17% 97
2021
Q1 		$976K Buy
20,247
+2,550
+14% +$123K 0.24% 83
2020
Q4 		$921K Buy
17,697
+1,900
+12% +$64.2K 0.23% 88
2020
Q3 		$423K Buy
15,797
+1,000
+7% +$23K 0.09% 141
2020
Q2 		$288K Buy
+14,797
New +$238K 0.06% 153

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

SlateStone Wealth's TGTX Position: Q1 2022 in Review

SlateStone Wealth sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 14,447 shares — an estimated $274K sold.

SlateStone Wealth first reported a position in TGTX in Q2 2020 and held it in 7 quarters. The position peaked at $976K in Q1 2021. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.

  • SlateStone Wealth reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
  • SlateStone Wealth sold 14,447 TG Therapeutics shares in Q1 2022, an estimated $274K.
  • SlateStone Wealth first reported a position in TG Therapeutics in Q2 2020 and held it in 7 quarters.
  • SlateStone Wealth's TG Therapeutics position peaked at $976K in Q1 2021.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.

Based on SlateStone Wealth's 13F filing for Q1 2022, filed 4 May 2022.